Tige Cycline Successfully Treats One Case of Relapsed Leukemia-drug-resistant Double Sepsis

preprint OA: closed CC-BY-4.0
📄 Open PDF View at publisher

Abstract

Abstract Background Nowadays, tigecycline is often used in combination with other antibiotics. To the best of our knowledge, this was the first documented use tigecycline alone for drug-resistant double sepsis in a patient suffering from leukemia.. The aim of this study is to reduce unnecessary drug combinations associated with tigecycline and use antibiotics reasonably. Methods The patient was a relapsed patient with advanced acute leukemia, with severe perianal infection and neutrophil deficiency. At the same time, blood culture suggested Acinetobacter luffi (Imipenem resistance) and Enterococcus faecium (vancomycin resistance). The doctor has no other choice according to drug susceptibility results. Tigecycline is used alone, and conventional doses are used . Results the patient's temperature gradually became normal, blood pressure was stable, blood in the stool stopped, perianal swelling subsided, pain was reduced, and infection improved. Conclusion generally speaking, tigecycline is a bacteriostatic agent; doctors are used to a combination of Tigecycline and other antibiotics in fighting infections.In this case, the patient's immunity is low.Tigecycline is used alone, and conventional doses are used to achieve the effect of curing double sepsis experience.This helps in the rational use of antibiotics.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-05-19T01:45:01.086888+00:00
unpaywall
last seen: 2026-05-22T02:00:06.705733+00:00
License: CC-BY-4.0